XNASBBLGW
Market cap2mUSD
Jan 07, Last price
52.04USD
1D
7.30%
IPO
4,273.11%
Name
Bone Biologics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
31.46%
Rev. gr., 5y
%
Revenues
0k
Net income
-9m
L
CFO
-10m
L+167.90%
Earnings
Feb 19, 2025
Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 9,428 | 3,665 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,428) | (3,665) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (2,181) | ||||||||
Tax Rate | |||||||||
NOPAT | (9,428) | (1,485) | |||||||
Net income | (8,949) -1,385.86% | 696 -143.21% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5,044 | 4,430 | |||||||
BB yield | -424.10% | -184.93% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (3,027) | (7,538) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (9,556) | (3,567) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 5,044 | 4,430 | |||||||
FCF | (9,428) | (1,485) | |||||||
| Balance | |||||||||
Cash | 3,027 | 7,538 | |||||||
Long term investments | |||||||||
Excess cash | 3,027 | 7,538 | |||||||
Stockholders' equity | (80,908) | (71,945) | |||||||
Invested Capital | 83,815 | 77,109 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 263 | 48 | |||||||
Price | 4.52 -91.02% | 50.33 -94.04% | |||||||
Market cap | 1,189 -50.35% | 2,395 -85.02% | |||||||
EV | (1,837) | (5,143) | |||||||
EBITDA | (9,428) | (3,665) | |||||||
EV/EBITDA | 0.19 | 1.40 | |||||||
Interest | 2,181 | ||||||||
Interest/NOPBT | |||||||||